nereus
Generic: tradipitant
nereus: developed by 1 company · 1 FDA decision.
nereus evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect nereus to VNDA; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could nereus → VNDA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
prevention of vomiting induced by GLP-1 receptor agonists
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) prevention of vomiting induced by GLP-1 receptor agonists | Phase 3 |
FDA Decisions1 records
NDA220152Type 1 - New Molecular EntityStandardOralCapsule
Frequently asked questions
Who is developing nereus?
nereus is being developed by Vanda Pharmaceuticals Inc..
What is nereus's latest FDA decision?
The most recent tracked FDA decision for nereus is Approval for 1 INDICATIONS AND USAGE NEREUS is indicated for the prevention of vomiting induced by motion in adults. NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults. ( 1 ), dated December 30, 2025.